U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07314541) titled 'A Phase Ia Study of KMY Tablets in Healthy Subjects' on Dec. 18, 2025.
Brief Summary: This is a Phase Ia, randomized, double-blind, placebo-controlled study conducted in healthy subjects. The study plans to enroll a total of 120 participants, with both males and females included in all parts.
The trial consists of three distinct parts:
Part A (Single-Ascending Dose, SAD): A total of 72 subjects will be enrolled to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of KMY Tablets.
Part B (Multiple-Ascending Dose, MAD): A total of 36 subjects will be enrolled to evaluate the safety, tolerability, and pharma...